Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

CellaVision, Audiocast, Q1'26

By Inderes4/24/2026, 9:00 AM
CellaVision

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Simon Østergaard
00:01 - 15:03

Thank you very much, and thanks for dialing in to this quarterly financial call. I have our CFO, Monica Johnson, with me, and we are pleased to present our results and answer any questions you may have subsequent to the presentation. So we just released the first quarterly report, and it was a soft quarter due to lower sales in EMEA; the quarter resulted in net sales that decreased by 14.6% to a revenue of 166 million. So that's an organic decrease of 6.6%, as we had almost 8% headwind on currency; EBITDA amounted to 40 million. So that corresponds to 24%. As we say in the report, EMEA is affected by inventory adjustment. With our main distribution partner. And that is what has caused this significant negative growth compared to the comparable quarter last year. So that's the bad news. There are no fundamental changes to our business model or the market conditions. But this is the situation that we announced today. We are also announcing that we have continued momentum in our strong region in Americas, and we continue to see double-digit organic growth in Americas. And furthermore, this is getting broader within APAC, we see traction to convert labs and we see positive development coming out here in Q1 with regards to our strategic direction. Since we've been investing in new product development for quite some years, and now we are starting to launch these new components. And there are good examples coming out here in Q1. We have launched the CellaVision® Bone Marrow Aspirate (BMA) Application. After we received the CE mark, which was planned for Q1, but we obtained it just before Christmas 2025. So we have started our sales campaigns. We've started participating at conferences and we're in the process of training our distribution partners Sysmex to really position this, I would say, great product to the clinical community. So we expect to see a funnel being built throughout 2026 and that will result in revenues contributing in the second half of this year. We've also launched globally our updated software. This is the largest software upgrade for our platform ever. So it contains both user interface and improved workflow and features. And also, for the new Di 60, higher turnaround. So more blood samples can be processed. So it's a very, very powerful package that is now available both to upgrade existing instruments and networks, but also as part of the new Di 60 systems. And then finally, in our investment program, it is important to emphasize that we are still extremely confident and we're pushing our next generation solutions with FPM, both for hematology. And then we're exploring our opportunities very successfully to also be deployed in other areas such as cytology and pathology. So let's unpack the P&L. So Net sales were 166 million, excuse me, representing -15% growth or -6.6% organic growth up against last year. We had a gross margin of 68%. And that entails also an increase in our amortization of capitalized development expenditures, given the bone marrow and the upgraded software program that I just talked about. So, here we are now depreciating 3 million versus 2 million. Operating expenses landed at 51% versus 41%. In fact, it's equivalent to a higher spend of operating expenses of 5 million. And that 5 million is actually also the difference in what we are capitalizing. So EBITDA was 40 million, representing 24%, which is, of course, lower than our expectations and a function of the miss in the top line that I will explain a little bit later. We are still investing in our R&D, but there are also changes to the maturity or early stage of the programs we are running, which is also a function of how much we can capitalize. So that's also part of the reason why you see a different capitalization of 12 million this quarter versus in the comparable quarter, 18 million. So, we had significant hardware investments in the comparable quarter that are not reflected in this quarter. So that's a function of the program. Finally, regarding operating cash flow. 62 million. We had 40 million, then plus the working capital. We had accounts receivable that contributed positively to our operating cash flow of 62. And then we had investments and financing activities that are deducted. And that results in a total cash flow of 42 million. Still, as always, a positive cash flow. And now with cash and cash equivalents, the company has 230 million sitting on the balance sheet. So the regional highlights. In America, it is really important for me, the team, and our partner to emphasize the strong momentum we have with 13% organic growth. So 2%, but a negative currency effect of 12 leads to 13% growth. And we saw continued strong adoption of our integrated large instruments for the hospital community around the US, we are focusing and pushing the concept of connected labs to position the DC one in these integrated health networks. So we are working very strongly together with our American partner organization. To push this, we also saw a little bit regarding the small lab segment that is served by the instrument. Regarding the DC one, we actually observed a slight instrument decline, which also followed a period of pent-up purchases of small instruments. Given the tariffs and uncertainties throughout 2025, there's a lot of activities going on to really serve this segment. And there's a lot of appetite for that value proposition of connecting that with our integrated solution for these networks. And yes, we mentioned some market uncertainties. I'd say demand-wise, there is still really a need, an ongoing appetite to digitalize the labs across the different markets that are immature and mature in very different degrees. So what we hear is that public funding is a little bit under pressure, given the defense situation of Europe, which does delay certain tender specs. So that's kind of the market condition, but the -32% growth or -26% organic growth is not related to the market. This is really a situation around the temporary reduction in excessive inventory that hit us in this Q1. So the root cause here is a number of excess units sitting in multiple affiliates. Probably over some time, that has happened to mitigate delivery risk from ERP implementations. As our partner Sysmex's fiscal year ends by the end of March, there's been a strong push to cut down and really examine where they have inventories. And that has resulted in obviously fewer orders, significantly fewer orders for us in this quarter. And that is really what we're reporting here. It's important for us to emphasize that we flagged this. Is it over? Is all inventory complete in Q1? We cannot promise that some inventory will not persist into the second quarter. So stock may still remain in Q2. However, we expect better instrument sales in Q2, and we don't expect negative growth, but it's a little bit too early to say what growth will come in Q2. So we're being extremely transparent and conservative here, but I think it is really the best of our current knowledge. However, as I said, it's early days with one month into Q2, and for APAC, we landed at 10% growth. So 22 million, of course, is up against smaller numbers, so to speak. Having said that, the positive thing is that we start to see traction across APAC. We have previously been very exposed in China, and we are seeing diversification and a broader demand for our solutions across Southeast Asia, which is super positive. We'll take the numbers, which on this slide are presented by product category. For instruments, the highlighted miss amounted to 86 million compared to 115 million in the comparable quarter, essentially representing the EMEA miss we are seeing; for the stable reagent business, what we have managed to do over the years, with APAC previously being insignificant, is now getting to a level where it starts to really contribute. It's across multiple countries as we have launched our classic stain portfolio across APAC together with Sysmex. And here this quarter, we reached almost 4 million versus a comparable figure of 1.4 million. So we are starting to see some traction here, which is truly a signal of a long journey and extremely positive, even though software and others saw a -2% change. So pretty much flat. I would say though, that the software is less than it was in the comparable quarter. And that is a function of less instruments. And then there's a little bit more on others, which entails spare parts and also our FX. So, on this final slide, our key takeaways. Yes, we are extremely transparent around our soft quarter, which is really due to the lower sales in EMEA. And this is the root cause for having only -7% organic growth, which is of course, not in line with our expectations. However, we still think that there are opportunities across EMEA. And that is also the signal we get from our partner that there are multiple opportunities across the different segments we operate in for Americas. Strong momentum. It continues. And also here, I would say there are opportunities with new products. And that leads me into the bone marrow. And other news that we report is that we have filed to the FDA our bone marrow application. So we're in process of registering our bone marrow application as a 510(k) and get clearance for that for the US so we can start commercializing the bone marrow application together with the DI-60 and our remote review software as a package to support the clinicians who are diagnosing. leukemias, lymphomas from bone marrow. And then again, I mentioned our software upgrade. There are multiple global training activities going on across the Sysmex organization to position our software 72, which allows the hospitals to get improved user interface and a better workflow, more speed if they go with the new Di 60. So that's really another pivotal thing. And then, as also mentioned in the beginning, we are extremely confident but also extremely committed development-wise to continue to push our relatively mature development program for our next-generation solution that entails our new microscopy technology under the name of FPM Fourier Ptychographic Microscopy, and are also exploring and seeing opportunities in adjacent segments such as cytology and pathology. So with that, I think I will close the presentation, and then Monica and myself would be happy to take any questions you may have. Thank you.

Operator
15:05 - 15:24

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Simon Østergaard from Danske Bank. Please go ahead.

Simon Østergaard
15:26 - 15:47

Yes. Thank you. Good morning everyone. So, starting off with the obvious question here on the inventory dynamics in EMEA, could you help us understand when this took place and how you see the stock levels turning out, given that this could potentially also affect the second quarter? So any more flavor here would be very helpful.

Simon Østergaard
15:49 - 16:29

Yes, thanks, Simon. I think when it took place, you can say we were informed in this quarter. So, I think the increase has probably been throughout last year when there were ERP implementations. That is how we understand the situation. And we believe that the majority of the stocking is probably digested throughout this quarter, but there may be a slight spillover of stock left in the subsequent quarter. That's the best information we've gotten.

Simon Østergaard
16:30 - 16:46

Gotcha, gotcha. And also, if you could give any more color on the European public healthcare budget constraints that you mentioned, what are your customers telling you now? And do you have any kind of timeline for when things could potentially improve?

Simon Østergaard
16:47 - 17:29

No, I think what we hear is that in general, and we all know that there is a debate in all countries, around investments into defense. And that is driving a little bit of pressure also on the healthcare side. So, when we discuss this with our partner, we see certain countries – it's not all countries – but there are countries, for example, the UK, where there appears to be a little bit of delay of tenders coming up as a result of the demand for financing other activities outside healthcare.

Simon Østergaard
17:32 - 17:55

Yeah, that makes sense. Makes sense. And also, focusing in the Americas, large instruments seem to be doing quite all right, but small instruments are still a bit muted. Could you help us understand? What initiatives are you taking and what is the go-to-market strategy to truly reach your full potential with the DC-1 instrument and on the smaller customer side?

Simon Østergaard
17:55 - 19:32

Yeah, sure. Yeah, I think it's doing okay. I would modify it. And I think they're doing extremely well. It's a large market where our partner has the vast majority of the market. So they continue to win across those mid and large segments. There are a lot of activities going on to embrace also the small lab segment, especially around the integrated health networks, where smaller labs are connected and administered under the large lab umbrella. So you can do the blood work distantly by placing these DC1s. And then you can remotely take the diagnostic decisions centrally at the large labs. So that value proposition and the way to set up these digital networks, both with the server structure and so forth. That's an ongoing training exercise towards our partner. This involves all the reps, and it's also a demonstration exercise towards the integrated health networks in the US that takes place in a very structured and a very focused way. And that value proposition has seen increased focus. Sysmex this year, this is a key focus, and this is what we believe will be part of the conversion of these labs over time. Sysmex this year, this is a key focus and what we believe will be part of the conversion of these labs over time.

Simon Østergaard
19:35 - 19:57

Yeah. Okay. Good, good. And maybe the final one from my end. On the bone marrow application, I think you're writing that you expected to contribute positively in the second half of the year. What kind of volumes are you expecting? And should we read this as it will be meaningful to group growth already this year, which is more a 2027 story?

Simon Østergaard
19:59 - 21:48

No, I think what we do here, it's always when you talk about launch, it's very important also to be aligned on what 'launch' means. The first step in our launch was actually getting the registration in place so that we could start the commercial launch activities. And that is where we are; we have positioned and made all the launch material. We've launched, we've gone live on Sysmex channels, various channels. We are very active. Last week, we participated at the EHA, a big European show for bone marrow and hematology. And here we presented our solution. So, we are launching from a marketing perspective. And obviously, the exercise in parallel is to train Sysmex to explain the value of our product, to demonstrate it, and to persuade the clinicians. Essentially, that's the sale process. So we're in the process of really getting Sysmex trained and competent in conveying our product and our solution. And that's what takes place pretty much from now on and onwards. And that will gradually build a funnel. And that's what we say that we expect that to translate into sales. We have the first couple of sales coming in. But it's more meaningful to talk about it in the second half, I would say; we expect it to contribute with a percentage or two in terms of company growth. That would be our ambition level. But let's see as we start building the channel, we are very confident that we have a very, very good offering. That's the initial feedback we get from the community.

Simon Østergaard
21:51 - 21:54

Super. Very clear. Thanks a lot. Thank you.

Simon Østergaard
21:54 - 21:56

Excellent, Simon. Thank you.

Operator
22:00 - 22:04

The next question comes from Christian Lee from Pareto Securities. Please go ahead.

Christian Lee
22:07 - 22:30

Thank you. And good morning, Simon and Monica. I have a couple of questions, please. Sure. I think you mentioned that you didn't expect negative growth in EMEA in the second quarter. If I heard you correctly here. Does this refer to EMEA overall or specifically to instrument sales in the region?

Simon Østergaard
22:31 - 23:14

My comment, and thank you for asking that question, is intended to clarify this. So my comment relates to the inventory issue. So that relates to the instrument. So there. But I would say that it probably translates to the quarter as well. My initial feeling is that it will not be what we've seen in Q1; however, we are being very transparent that, while we don't necessarily see the actual stock level being depleted in Q2, we do expect an increase if we compare Q2 to Q1, anticipating selling more instruments and achieving no negative growth.

Christian Lee
23:15 - 23:29

Okay. Clear. And there also appear to be elevated inventory levels of smaller instruments in the Americas. Do you see a similar risk of inventory overhang impacting sales in the second quarter there?

Simon Østergaard
23:31 - 24:22

And for the US specifically, Christian, is that? Yes, for the US, I don't foresee any inventory issues. With regards to the larger instruments, only the small instruments, that could still be the case. That is a little bit of a journey. And also because of the major uncertainty and mixed signals that have come out with regards to tariffs, which has influenced the stock situation on the American side. Having said that, I'd say after the sales meeting, we've really ramped up and focused on this connectedness concept. And we and our colleagues are really hanging on to that now and really doing a great job in pushing it. So we expect that the demand will increase throughout the year.

Christian Lee
24:25 - 24:39

Okay. Perfect. And if we exclude the impact from smaller instruments and currency headwinds in the first quarter, would instrument sales still have shown a double digit decline or been closer to flat? That.

Simon Østergaard
24:46 - 24:51

Maybe you can help me out here. Yeah, I would.

Monica Johnson
24:54 - 24:56

More closer to flat.

Simon Østergaard
24:57 - 24:58

On the large instrument.

Monica Johnson
24:58 - 25:00

Right on the large instrument in EMEA we're talking about.

Simon Østergaard
25:03 - 25:06

Yeah, maybe. Maybe.

Christian Lee
25:06 - 25:13

Maybe slightly flattish for the larger instruments or for the whole instrument.

Simon Østergaard
25:13 - 25:39

I think it's fair also to emphasize here that, so that's why I'm doing the math. We're up against a very tough compare. That's, that's important to say. So the Q1 in 2025 was actually a very strong quarter in EMEA. Having said that, that's where we aspire to be. But when we talk about growth, I think it's important to emphasize what we're up against.

Christian Lee
25:43 - 25:56

Okay. Thank you. And my last question. R&D expenses. Almost 30 million SEK in the first quarter. Should we expect this level to persist throughout the year, or was Q1 elevated?

Monica Johnson
25:58 - 26:43

Yeah. So maybe I can take that one. The 30 million SEK on R&D spending is also related to that. We are capitalizing less at the moment. And we see that the organization is working on early-stage projects, and we're looking into starting to capitalize some of those in Q2 or Q3. So when we start capitalizing that, then you will see somewhat of a decrease on R&D costs. At that stage. So, in Q2 and Q3, you would see somewhat of a decrease, but that will come with an increased CapEx then.

Christian Lee
26:46 - 26:48

Okay, great. Thank you very much.

Simon Østergaard
26:48 - 26:56

Yeah, Christine, it's a little bit of a portfolio shift due to the accomplishment of launching these products. So that's the process we go through.

Christian Lee
26:58 - 26:59

Okay, perfect. Thank you.

Operator
27:02 - 27:08

So the next question comes from Ulrich Trattner from DNB Carnegie. Please go ahead.

Simon Østergaard
27:11 - 27:56

Good morning, Simon and Monika. Just essentially a few follow-ups on my end. Looking in hindsight here for the EMEA region, I don't see a single quarter throughout 25. Where are we supposed to see any type of elevated levels of inventory build-up, or did it just gradually happen throughout the entire 2025? Because if I look at the first half of 25, you had 88 million in sales. If I look at the second half of the year, you had 88 million in sales. So, essentially, my first question is where we are supposed to see the inventory build-up in historical numbers, please.

Simon Østergaard
27:57 - 29:24

It was spread out. To the best of our knowledge, the first event actually goes back. So there are two disruptions taking place. One was back in autumn 2024 when Sysmex changed their inventory there. Oh, sorry. Their warehouse in Hamburg, which was a disruption. And then followed by SAP implementations that have caused quite some affiliates to actually build up a little bit of local stocks. So they were able to supply and install the instruments when the customer was waiting to do so. And that has persisted gradually over time to mitigate disruptions from both the SAP implementation and the distribution center. So that is what has been sitting in apparently throughout quite a few quarters, small blips, which adds up to now. Prior to this fiscal year closing, there was an attempt to really work on the capital tied up in instruments. So their working capital, their inventory level. And this is where we saw this major dip, which came a little bit as a surprise on our side, but that is the situation.

Simon Østergaard
29:27 - 29:55

Okay. So, to get some clarity, if we were to adjust for this up to 2025, would we have reached organic growth or, as you presented, 5% growth in 2025? Yes. Some negative effects, some headwinds there, but it's not that much growth from EMEA in 2025. So, adjusting for this, which was growth negative in 2025 by your estimates.

Simon Østergaard
29:58 - 30:00

No, I'd say more flattish.

Simon Østergaard
30:04 - 30:28

Okay. Then because I understand your uncertainty here and I guess lack of transparency from Sysmex's side, what's your sort of confidence levels that we have churned out the built-up inventory in the first half of 2026, given the prolonged buildup of inventory heading into this?

Simon Østergaard
30:29 - 32:11

I think it's important for me to emphasize that we would never excuse them for not being transparent. I think this was also a much larger organization. So this is a symptom of running a global business in EMEA with multiple entities. So this also came to their attention. And then they have been super transparent around the situation. I think that's important for me to emphasize. And, having said that, and that's what we try to communicate. The biggest inventory hit, we've already taken. And then there may be some spillover. So if they don't come down to quite the level, then there will be a little bit sitting in Q2. However, we already see that we're on a positive trajectory when we compare to this quarter. And this is why we say we are confident that we are at least not coming out with negative instrument growth in this quarter that we're in. We can certainly emphasize that. Having said that. Over time, I still think that there is. So we're still working on the market opportunity. It is also emphasized that the tender opportunities and market opportunities remain. So there's a solid foundation for the business still. Of course, the macro environment, we sense that it's more influenced in Europe than what we see in the US. There's also a factor, and that's not necessarily a macroeconomic one. It's probably also the more private hospital setting with the networks, etc. where we have a working model with Sysmex.

Simon Østergaard
32:13 - 32:47

And just on the market environment and as you mentioned, some delays in tender activities, but even from absolute numbers here, obviously you have this inventory, I'm trying to find some confidence level here in absolute numbers. And I'm not really sure which period historically to look at. Should we look at post-COVID? Should we look at, I think five years, where interest rate fear is a consideration?

Simon Østergaard
32:47 - 32:48

Um, yeah.

Simon Østergaard
32:48 - 32:51

If you look at the worst macro environment now compared to 2025.

Simon Østergaard
32:53 - 33:19

Probably a little bit more unpredictable. That's kind of the signal we get that it's getting a little bit more unpredictable as opposed to a year ago. Um, okay. That would be the frame. I wouldn't go back to Covid and so forth. Right? However, if your question was also related to the inventory period, I'd say six quarters. Okay.

Simon Østergaard
33:20 - 33:33

Great. That's fine. I think that's all on my end, and I'll get back into the queue. Thank you, Simon, for taking my questions.

Simon Østergaard
33:33 - 33:35

Of course. All right. Pleasure. Thank you.

Operator
33:37 - 33:50

As a reminder, if you wish to ask a question, please dial pound key on your telephone keypad. The next question comes from Ludvig Lundgren from Nordea. Please go ahead.

Ludvig Lundgren
33:52 - 34:09

Yes. Hi. So, starting off in EMEA, I just wonder if you saw any effects or weakness in the Middle East here in Q1. So starting off in EMEA, I just wonder if you saw any effects or weakness in the Middle East here in Q1. And if you expect any effects from this in Q2.

Simon Østergaard
34:11 - 34:34

In the Middle East, we've actually seen effects on the reagent side where it's been very challenging to deliver. So we've definitely seen some impact there. That would be the main point I would emphasize here, Ludwig.

Ludvig Lundgren
34:36 - 34:41

Okay, great. And is it possible to quantify that, a few million lost sales or something?

Simon Østergaard
34:41 - 34:44

Yeah, that's probably appropriate.

Ludvig Lundgren
34:46 - 35:04

Great. And then secondly, I wonder on the bone marrow application, you mentioned that you have filed the 510(k). So just when was this filed? And have you gotten any indication of when they could come back? I think they typically aim for a 90-day review period, right?

Simon Østergaard
35:04 - 36:52

Yeah. No, that's right. We also follow what the formal process is, and so forth. So I think to the best of my knowledge, we filed on the 11th of March. And then we have started the interactions with the FDA. We also get feedback from the diagnostic community that the FDA's responsiveness has probably increased lately. I'd say over the last year or two, that's kind of the general sense in the industry. And so if you ask me when do we expect it to come? I must emphasize, of course, we need to qualify to get the 510(k). That's the first thing. So there's always a little bit of a probability there. Having said that, we expect it to go well and to have this in 2026; best case would be mid-2026. That's a little bit on the best case. But assuming we get it, then we do expect to get it sometime in this year. There are some phases in terms of questioning, etc. And they stop the clock. So we're up against a timeline which is pretty controlled. But I'd say 2026 is what we aim for, and hopefully we have good news at some point; the earlier, the better. So we've obviously also started our launch considerations with our partner on this pivotal product to supplement our offering. Thanks.

Ludvig Lundgren
36:55 - 36:57

Great. Thanks. I'll jump back into the queue.

Simon Østergaard
36:57 - 36:58

Cool.

Operator
37:01 - 37:07

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Simon Østergaard
37:09 - 39:27

Thank you very much. And first of all, thanks to everybody for taking the time to dial in and following us here at CellaVision. So I will close the call by saying that the Q1 results of course represent a mixed bag across the regions. It is important to confirm that we have momentum in our strong market position in the US. We are reporting an unforeseen inventory adjustment in EMEA. So we are set. This is a temporary blip, which is also the nature of our business model, I should say. Not that we like surprises, but that is what we need to deal with. And then I think it's also important to emphasize that we are really expanding across Southeast Asia. So I'm looking forward to share further development in those regions. And then finally, you've seen that things are starting to come out of the Power of Focus with the product launches. So we are very excited about that. And I want to use the opportunity to close the call also by thanking our partner organizations, both on the development side, when we have assessed our products, but also now that we are launching, training the staff, and rolling it out to build pipelines that can translate into additional sales. And so we can just emphasize that our leading product offering and the underlying market demand remains intact and unchanged. With this report, despite this blip on the inventory side. And with that, I'll close the call and I'm looking forward to report the next time we will have our Annual General Meeting here in Lund on the 28th. So on Tuesday, and then the next Interim Report will be published on the 17th of July, 2026. So I'm looking forward to presenting that report and to take any questions you may have. With that, I wish you a good day. Thanks for listening in.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…